CONTINUE TO SITE

OR WAIT null SECS

Cataract Surgical Case Study Cataract Therapeutics Glaucoma Insights Branded vs Generics CME Activities Dry Eye Viewpoint Diabetic Eye Disease Viewpoints Diabetic Eye Disease Podcast Dry Eye Concepts Management of Dry Eye Viewpoints Ocular Toxicity in Myeloma WetAMD Viewpoints

Clinical

View More Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

All News Blogs COVID-19

Expert Interviews Medical World News Podcasts Viewpoints Insights

Health Law & Policy Money Matters Personal Finance Practice Management

Conferences

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Digital Edition Europe Ophthalmology Times Modern Retina Supplements and Featured Publications

Transaction is a surprise, but makes sense, analysts say

December 1, 2004

Although the news of Advanced Medical Optics Inc. (AMO) buying VISX caught many on Wall Street off guard, several analysts are saying the deal makes sense in retrospect.

Related Content:

Personal Finance

Planning for financial safety in uncertain times

What can we learn from COVID-19?

What we've learned from the commonalities of financial aspirations, fears